Abstract:Background: Delirium is a prevalent neuropsychiatric medical phenomenon that causes serious emergency outcomes, including mortality and morbidity. It also increases the suffering and the economic burden for families and carers. Unfortunately, the pathophysiology of delirium is still unknown, which is a major obstacle to therapeutic development. The modern network-based system biology and multi-omics analysis approach has been widely used to recover the key drug target biomolecules and signaling pathways associated with disease pathophysiology. This study aimed to identify the major drug target hub-proteins associated with delirium, their regulatory molecules with functional pathways, and repurposable drug candidates for delirium treatment. Methods: We used a comprehensive proteomic seed dataset derived from a systematic literature review and the Comparative Toxicogenomics Database (CTD). An integrated multi-omics network-based bioinformatics approach was utilized in this study. The STRING database was used to construct the protein-protein interaction (PPI) network. The gene set enrichment and signaling pathways analysis, the regulatory transcription factors and microRNAs were conducted using delirium-associated genes. Finally, hub-proteins associated repurposable drugs were retrieved from CMap database. Results: We have distinguished 11 drug targeted hub-proteins (MAPK1, MAPK3, TP53, JUN, STAT3, SRC, RELA, AKT1, MAPK14, HSP90AA1 and DLG4), 5 transcription factors (FOXC1, GATA2, YY1, TFAP2A and SREBF1) and 6 microRNA (miR-375, miR-17-5, miR-17-5p, miR-106a-5p, miR-125b-5p, and miR-125a-5p) associated with delirium. The functional enrichment and pathway analysis revealed the cytokines, inflammation, postoperative pain, oxidative stress-associated pathways, developmental biology, shigellosis and cellular senescence which are closely connected with delirium development and the hallmarks of aging. The hub-proteins associated computationally identified repurposable drugs were retrieved from database. The predicted drug molecules including aspirin, irbesartan, ephedrine-(racemic), nedocromil, and guanidine were characterized as anti-inflammatory, stimulating the central nervous system, neuroprotective medication based on the existing literatures. The drug molecules may play an important role for therapeutic development against delirium if they are investigated more extensively through clinical trials and various wet lab experiments. Conclusion: This study could possibly help future research on investigating the delirium-associated therapeutic target biomarker hub-proteins and repurposed drug compounds. These results will also aid understanding of the molecular mechanisms that underlie the pathophysiology of delirium onset and molecular function.

Preclinical and translational models for delirium: Recommendations for future research from the NIDUS delirium network

Risk Predictive Models for Delirium in the Intensive Care Unit: a Systematic Review and Meta-Analysis.

A roadmap to advance delirium research: Recommendations from the NIDUS Scientific Think Tank

Translational animal models for Alzheimer's disease: An Alzheimer's Association Business Consortium Think Tank

The Pathophysiology and Biomarkers of Delirium

Addressing the Discrepancies Between Animal Models and Human Alzheimer's Disease Pathology: Implications for Translational Research

Precision‐based approaches to delirium in critical illness: A narrative review

Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications

ICU Delirium Prediction Models: A Systematic Review

Role of glia in delirium: proposed mechanisms and translational implications

Delirium disorder: Integrating delirium and acute encephalopathy

A Comprehensive Review on Preclinical Alzheimer's Disease Models: Evaluating their Clinical Relevance

Modeling the neuroimmune system in Alzheimer's and Parkinson's diseases

Animal Models for Alzheimer’s Disease: a Focused Review of Transgenic Rodent Models and Behavioral Assessment Methods

Preclinical animal models and assays of neuropsychiatric disorders: Old problems and New Vistas - introduction to the special issue

Exploration of key drug target proteins highlighting their related regulatory molecules, functional pathways and drug candidates associated with delirium: evidence from meta-data analyses

Lost in translation: Inconvenient truths on the utility of mouse models in Alzheimer's disease research

Priorities for research on neuromodulatory subcortical systems in Alzheimer's disease: Position paper from the NSS PIA of ISTAART

Abstract TP14: Translational Modeling Of Morphological And Physiological Features Of Vascular Dementia: A Review

Insight into the emerging and common experimental in-vivo models of Alzheimer's disease

Past Misconceptions and Future Prospects